Media headlines about Wave Life Sciences (NASDAQ:WVE) have trended somewhat positive on Wednesday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Wave Life Sciences earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.4862648663846 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have effected Accern’s rankings:
- Equities Analysts Set Expectations for Wave Life Sciences Ltd’s Q1 2019 Earnings (WVE) (americanbankingnews.com)
- Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update (finance.yahoo.com)
- Post-Traumatic Stress Disorder: A Review of Therapeutic Role of Meditation Interventions (lankaweb.com)
- Wave Life Sciences (WVE) PT Raised to $60.00 (americanbankingnews.com)
WVE has been the topic of a number of research analyst reports. Zacks Investment Research lowered Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. BidaskClub raised Wave Life Sciences from a “hold” rating to a “buy” rating in a report on Friday, January 26th. TheStreet raised Wave Life Sciences from a “d+” rating to a “c-” rating in a report on Friday, January 5th. Leerink Swann reissued an “outperform” rating on shares of Wave Life Sciences in a report on Sunday, March 4th. Finally, SunTrust Banks lifted their price objective on Wave Life Sciences to $60.00 and gave the stock a “buy” rating in a report on Friday, March 9th. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $47.20.
In other news, insider Michael A. Panzara sold 511 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $52.10, for a total transaction of $26,623.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Chris Francis sold 21,639 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $55.40, for a total value of $1,198,800.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,466 shares of company stock valued at $1,321,808. 53.00% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Wave Life Sciences (WVE) Share Price” was first published by BBNS and is owned by of BBNS. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://baseballnewssource.com/2018/03/14/wave-life-sciences-wve-receiving-somewhat-positive-news-coverage-report-finds/1890374.html.
About Wave Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.